These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12869459)

  • 41. [The 10-minute consultation. Accidental finding: hyperkalemia. Caution with analgesics and bananas].
    Lenz T
    MMW Fortschr Med; 2005 Jan; 147(4):59-60. PubMed ID: 15745346
    [No Abstract]   [Full Text] [Related]  

  • 42. Normal ECG or peaked T waves?
    Hancock EW
    Hosp Pract (1995); 1998 May; 33(5):19-20. PubMed ID: 9606350
    [No Abstract]   [Full Text] [Related]  

  • 43. Spironolactone and congestive heart-failure.
    Georges B; Beguin C; Jadoul M
    Lancet; 2000 Apr; 355(9212):1369-70. PubMed ID: 10776778
    [No Abstract]   [Full Text] [Related]  

  • 44. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of low-dose spironolactone on resistant hypertension.
    Engbaek M; Hjerrild M; Hallas J; Jacobsen IA
    J Am Soc Hypertens; 2010; 4(6):290-4. PubMed ID: 21130975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
    Abolghasmi R; Taziki O
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spironolactone in patients with heart failure.
    Larkin RJ; Atlas SA; Donohue TJ
    N Engl J Med; 2000 Jan; 342(2):132-3; author reply 133-4. PubMed ID: 10636751
    [No Abstract]   [Full Text] [Related]  

  • 51. [Urea and spironolactone therapy].
    Schwarzbach W; Bunzl W
    Munch Med Wochenschr; 1973 Jan; 115(3):76-80. PubMed ID: 4739290
    [No Abstract]   [Full Text] [Related]  

  • 52. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heart failure drug poses potassium problems. When using "the water pill" spironolactone, watch your potassium intake and check your levels.
    Harv Heart Lett; 2004 Dec; 15(4):3. PubMed ID: 15704264
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spironolactone-potion or poison?
    Drug Ther Bull; 2017 Feb; 55(2):13. PubMed ID: 28153847
    [No Abstract]   [Full Text] [Related]  

  • 56. [Renal effect of treatment for heart failure].
    Rasmussen ZZ; Barfod T; Klit J
    Ugeskr Laeger; 2009 Feb; 171(9):718. PubMed ID: 19257999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hyperkalemias in cardiac patients].
    Raynaud R; Brochier M; Raynaud P; Fauchier JP
    Sem Hop; 1974 Oct; 50(40):2463-70. PubMed ID: 4374758
    [No Abstract]   [Full Text] [Related]  

  • 59. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diuretics, ACE inhibitors and NSAIDs--the triple whammy.
    Thomas MC
    Med J Aust; 2000 Feb; 172(4):184-5. PubMed ID: 10772593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.